Exclusives - Spark Newswire

1 minute read

EXCLUSIVE: Annovis Bio CEO Says Co. Planning To Continue Trials For ANVS401 Into Phase 3 For Both Parkinson’s And Alzheimer’s

By Benzinga Newsdesk

Today, 2:15 AM

https://www.youtube.com/watch?v=5KqPqg3Ae8Yhttps://www.youtube.com/watch?v=5KqPqg3Ae8Y

ANVS

1 minute read

EXCLUSIVE: Annovis Bio President & CEO, Maria L. Maccecchini, Ph.D. Now Interviewing On Benzinga’s Power Hour Show

By Zoltan Suranyi

Today, 2:15 AM

Click To Tune In Here... https://www.youtube.com/watch?v=5KqPqg3Ae8Y

ANVS

1 minute read

EXCLUSIVE: Seaport Global Acquisition Corp Merger Partner, Redbox CEO, Galen Smith Now Interviewing On Benzinga’s SPACS Attack Show

By Zoltan Suranyi

Today, 2:15 AM

Click To Tune In Here... https://www.youtube.com/watch?v=Qr6Q3Lu6JXE

SGAM

1 minute read

EXCLUSIVE: Grom’s Curiosity Ink Developing New IP Franchise – The Pirate Princess

By Vandana Singh

Today, 2:15 AM

Grom Social Enterprises Inc's (NASDAQ: GROM), Curiosity Ink Media is developing The Pirate Princess, a new, original intellectual property (IP) franchise slated for global theatrical distribution.

GROM

1 minute read

EXCLUSIVE: Annovis Bio’s Parkinson’s Candidate Improves Speed, Motor Function Vs Placebo

By Vandana Singh

Today, 2:15 AM

Annovis Bio Inc (NYSE: ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD). Data from 54 patients found that once-daily ANVS401 was superior to placebo in improving motor function.

ANVS